

ARGENTUM PHARMACEUTICALS LLC
Petitioner

v.

ALCON RESEARCH, LTD
Patent Owner

Patent No. 8,791,154
Issue Date: July 29, 2014
Title: HIGH CONCENTRATION OLOPATADINE
OPHTHALMIC COMPOSITION

Inter Partes Review No. 2016-00544

**Affidavit of Christopher J. Mandernach in Support of
Motion for *Pro Hac Vice* Admission Pursuant to 37 C.F.R. § 42.10(c)**

2. This affidavit is given in support of the patent owner Alcon Research, Ltd. Motion for *Pro Hac Vice* Admission.

3. I am a member in good standing of the bars of Minnesota and the District of Columbia.

4. I have never been suspended or disbarred from practice before any court or administrative body.

5. No court or administrative body has ever denied my application for admission to practice before it.


6. No court or administrative body has ever imposed sanctions or contempt citations on me.

7. I have read and will comply with the Office of Patent Trial Practice guide and the Board's Rules of Practice for Trials set forth in part 42 of 37 C.F.R.

8. I understand that I will be subject to the USPTO Code of Professional Responsibility set forth in 37 C.F.R. §§ 11.101 et seq. and will be subject to disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

9. I have applied to appear *pro hac vice* in 3 other proceedings before the Office in the last (3) years: (1) *Apotex Corp. v. Alcon Research, Ltd.*, IPR2013-

10. I am familiar with the subject matter at issue in the present proceeding. This familiarity comes from my experience representing Patent Owner as trial counsel in related district court litigation in the United States District Court for the District of Delaware in the following consolidated case: *Alcon Research, Ltd. v. Watson Laboratories, Inc., Lupin Ltd, and Lupin Pharmaceuticals, Inc.*, Civil Action No. 15-1159-SLR-SRF (D. Del.).



Christopher J. Mandernach

Sworn to and subscribed before me
this 2nd day of August, 2016.



Notary Public

